IDEMIA
16.6.2021 13:32:04 CEST | Business Wire | Press release
The Project Embarque + Seguro 100% Digital Boarding System, using the Brazilian government’s facial recognition, arrives this Tuesday (June 15) at the Congonhas Airport (SP). For the first time in the world, passengers on the air shuttle service between the capitals of São Paulo and Rio de Janeiro will participate in the simultaneous testing of this end-to-end technology without the need to present neither a boarding pass nor an identification document. The Project of the Ministry of Infrastructure, developed in partnership with Serpro and the Special Secretariat of Debureaucratization, Management and Digital Government of the Ministry of Economy, has already been tested at the airports of Florianópolis (SC), Salvador (BA), Santos Dumont (RJ) and Belo Horizonte (Confins).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210616005505/en/
After the approval of the pilot project, the Federal Government will move forward with actions to effectively implement the technology in major Brazilian airports. The technology aims at making the boarding process at airports more efficient, agile, and secure. "It is the first time that tests are carried out simultaneously in two of our airports, thus establishing, in an unprecedented way, a 100% biometric air shuttle between RJ / SP, which has the fifth-largest movement in the world", highlights the executive secretary of MInfra, Marcelo Sampaio.
Throughout the day, Azul Linhas Aéreas’s passengers travelling between Congonhas and Santos Dumont airports will be invited to try the biometric facial recognition technology to access both boarding area and aircraft at both terminals. "Embarque + Seguro combines biometric validation and data analysis, ensuring an accurate, agile and secure validation of the identity of passengers, who can thus travel with more comfort and tranquility. The solution complies with the General Data Protection Law (LGPD) and is premised on security in the processing of personal data against misuse or unauthorized use", emphasizes the president of Serpro, Gileno Barreto.
For the president of Infraero, Brigadier Paes de Barros, "the air shuttle’s Embarque + Seguro unites two essential items that streamline the boarding processes, which are safety and ease for the passenger and the entire civil aviation system".
According to the Director of Public Security & Identity (PSI) of IDEMIA in Brazil, Márcio Lambert, "Facial recognition is a global trend and the Project Embarque + Seguro, jointly carried out by Minfra and Serpro, shows that Brazil is on the right track to airport digitalization. IDEMIA’s technology is applied in the most modern airports around the world, such as Changi in Singapore, and offers a high level of security for passengers, airlines, and airport operators, as its algorithm is highly accurate, reaching a extremely high authenticity rate in the identification of individuals. IDEMIA is proud to participate in this project along with Brazil’s Federal Government and to enable the world’s first 100% end-to-end digitized boarding system in an executive air shuttle service".
"The latest Global Passengers Research conducted by the International Air Transport Association (IATA) says that 70% of interviewees are willing to share their biometry for identification purposes during the boarding process. Our global expertise contributes to meeting society’s need to fly again. This innovative project developed by the Federal Government allows travelers to enjoy a quieter, safer and more comfortable boarding experience and puts Brazil at the forefront of the digital transformation movement. IDEMIA as a global leader in augmented identity has the mission to facilitate the flow of passengers by creating the possibility to interact and travel in a more connected way. To participate in the first air shuttle with an end-to-end fully digitized boarding system, in both airports, is an important milestone in our history,” explains Rodrigo Costa, PSI business development director at IDEMIA LATAM.
The MFACE technology, developed by IDEMIA, captures facial biometrics in seconds, making the boarding process even more agile, avoiding queues and delays. The solution combines the convenience and security of data validation, respecting the privacy of passengers according to the GDPR, and ensures a more hygienic process by eliminating document and paper handling, thus avoiding the risk of contamination.
"The control of IDEMIA’s biometric system follows high-quality, reliability and safety standards and offers more agility and comfort to passengers, turning the airport operational process more intelligent, the airline passenger identification more accurate, and generates the security required by the government," adds Márcio Lambert.
How it works
When checking in at the airport, the passenger of Azul Linhas Aéreas is invited to participate in the project. If the passenger agrees, then a message is sent to the cell phone informed in the application, requesting authorization to obtain the passenger’s data, including the social security number and a photo. Upon consent, the airline attendant, using the application developed by Serpro for this purpose, performs the biometric validation of the citizen, comparing the data and the photo taken on the spot with the government databases.
After validated, the passenger is released to enter the departure hall and the aircraft passing through biometric control points, whose cameras perform the passenger’s identification without the need for the user to present any document or boarding pass.
Total Security
In the pilot project, indicators such as queue time reduction, access to the departure hall and aircraft are measured, in addition to operating costs. With the tests, it is expected that airport security increases, as facial recognition allows an accurate identification of passengers.
"We are moving towards a fully secure biometric boarding at every airport in the country. In addition to the process being safe from the sanitary point of view, by eliminating the handling of papers during the pandemic, it guarantees the total protection of users' data, because the Embarque + Seguro 100% Digital Boarding System meets all the precepts of the LGPD", says Marcelo Sampaio.
Partnerships
Serpro is MInfra’s strategic partner in the country's transportation digital agenda, but Embarque + Seguro also has the collaboration of airlines and airports where the tests have been carried out, which has enabled the improvement of the project at each stage. The air shuttle pilot test is being implemented with the support of Infraero and Azul Linhas Aéreas; and the technology of facial identification stations was developed by Digicon, IDEMIA and Azul/Pacer companies.
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated, and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors. With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com
/ Follow @IdemiaGroup on Twitter
View source version on businesswire.com: https://www.businesswire.com/news/home/20210616005505/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 07:10:00 CEST | Press release
Collaboration will connect seamless payments, in-app digital engagement and AI-powered travel services to enhance the visitor journey, empower businesses of all sizes and unlock wider cross-border commerce opportunities Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Mal
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 07:00:00 CEST | Press release
Patient-reported outcomes from a phase II study of nemolizumab in children aged 2 to 11 with moderate-to-severe atopic dermatitis show meaningful reductions in itch severity, better sleep and improved quality of life, maintained for a year1 Currently, there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis, despite the high unmet need – the disease can significantly reduce quality of life for children and create burden on their families2-8 These findings expand on the clinical evidence base for nemolizumab, which has multiple global approvals for adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis, and adults with prurigo nodularis9,10 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 02:30:00 CEST | Press release
− ORZEYFUL is now available in Japan and China following approvals within a month of each other by China’s National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA) and Japan’s Ministry of Health, Labour and Welfare (MHLW) − Discovered by Takeda scientists in Japan, ORZEYFUL is the lead medicine in Takeda’s orexin franchise, with multiple programs for sleep-wake disorders and conditions where orexin biology plays a role − ORZEYFUL set to launch next month in the U.S., following completion of DEA scheduling; Health Authority submissions underway worldwide Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re ex
Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 02:10:00 CEST | Press release
Celltrion to showcase its broad IBD portfolio, including Remsima™ IV, Remsima™ SC, the newly launched Remsima™ IV Liquid formulation, Steqeyma™ and Yuflyma™Symposium and Meet the Experts sessions to highlight long-term clinical evidence and real-world experience with subcutaneous (SC) infliximab (Remsima™ SC) across different IBD patient scenarios Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to ex
ProcureTEX Returns for Its Second Year, Bringing AI and Best-of-Breed Procurement Technology to Amsterdam14.10.2026 18:26:00 CEST | Press release
Founding partners Beroe, Keelvar and Zip bring back the community-driven event with a practitioner-shaped agenda spanning real-world AI use and the future of procurement ProcureTEX, the community-driven event for best-of-breed procurement technology, returns for its second year on November 3, 2026, at Circa in Amsterdam. Following its London debut in 2025, the event sharpens its focus on how AI is reshaping procurement. It will bring together over 250 procurement leaders and digital transformation teams from large enterprises, with vetted best-of-breed technology providers, to see AI agents and interoperable tools working together on real enterprise challenges. Co-founded by Beroe, Keelvar and Zip, the event is built on the belief that the future of procurement isn’t a monolithic all-in-one suite, but an ecosystem of best-of-breed tools working together. It is designed for procurement and enterprise leaders seeking scalable, modern solutions, whether they’re driving transformation, fru
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
